The revised malaria death toll suggests a need for research into uncertainties in controlling neglected tropical diseases, says Mark Booth.

Much progress has been made in genomics research, says Stephen Baker, but the impact on public health is limited in the developing world.

Few causes are more worthy of funding than vaccines, says Priya Shetty, and the developing world relies on GAVI getting the billions it needs.

After recent gains against trypanosomiasis, new diagnostic and treatment tools mean we can make the final push, says Priya Shetty.

The funding stream for partnerships between the pharmaceutical and public sectors cannot be allowed to dry up, says Priya Shetty.

It is time to turn our attention to mental health in poor countries, argues Priya Shetty.

Chagas disease has gone beyond Latin America and, today, is a challenge for non-endemic countries, say José R. Coura and Pedro A. Viñas.

Innovating for health is about more than drug development. It means new ways of delivering and using existing technologies, says Priya Shetty.

Neglected diseases can be added to broader diagnostic development projects at little extra cost, say Joseph Mathu Ngung'u and colleagues.

Collaborative research between the United States and Islamic countries can reduce disease and promote peace, says vaccinologist Peter J. Hotez.

Sandeep P. Kishore and colleagues call on universities to focus on research for neglected tropical diseases.

A Nature editorial praises GlaxoSmithKline for sharing its database of potential malaria drugs and urges others to follow suit.

A global fund for drug innovators could enable them to tackle diseases that mainly affect the poor, say Amitava Banerjee and colleagues.

Poor countries need support to participate in genomics research, say Josefina Coloma and Eva Harris in PLoS Medicine.

Interrupting funding for mass treatment of lymphatic filariasis can lead to a quick resurgence in the disease, say Kimberly Won and colleagues.

A lack of political will to create vaccines is causing millions of deaths a year due to infectious diseases, says Manuel Elkin Patarroyo.

The biotech industry has advantages over pharma for drug discovery for neglected diseases, say Joanna E. Lowell and Christopher D. Earl.

GlaxoSmithKline plans to cut medicine prices and create a 'patent pool' — but does any of this reflect a real drive to boost the health of the poor?

While progress has been made in tackling lymphatic filariasis, we are still long way from eliminating the disease, says David H. Molyneux.

Eliminating schistosomiasis means using strategies that combine drug delivery, water management and snail control, says Charles H. King.